Billion dollar club grows
- April 24 elections roundup: Four policemen, two polling officers killed in Maoist attack
- Thousands turn up at Narendra Modi's Varanasi roadshow, BJP's PM candidate files nomination papers
- From Marandi vs Soren to Deora vs Sanyal: Top 5 battles in Lok Sabha polls Phase 6
- Rahul Gandhi joins sister Priyanka in attacking Narendra Modi on snoopgate
- IPL 7 Live Cricket Score, KKR vs RCB: RCB strong in chase against KKR
Although there were no large M&As or IPOs in 2012, India has a dozen companies in the generic space with a market cap of more than $1 billion and seven with a market cap of more than $3 billion. After Teva, the generics club is dominated by Indian pharma
Financially, 2012 has been a successful year for the Indian health sciences industry, with sizeable shareholder value creation and rebound in deal activity (especially outbound); however, there was almost no activity on the IPO front. On the business front, most companies reported good results—a stark contrast to the dismal performance of other manufacturing sectors in corporate India.
In retrospect, there are some crucial trends that can be identified.
Limited large M&As
We haven't seen a deal comparable to Nicholas-Abbott or Paras-Reckitt in the last two and a half years. While there have been several murmurs of a large deal in media circles, nothing seems to have fructified yet. The biggest challenge on closures continues to be valuation expectations of the Indian promoter. Any big pharma deal announcement in the sector in 2013 would, in all probability, throw up a new benchmark for valuing multiples. The earlier marquee deals (Nicholas, Paras, Ranbaxy) have redefined the way global companies view Indian businesses and we, at Candle Partners, believe this trend will only continue.
Sub-$250 million space
Surprisingly, in the mid-sized deals space, specifically the API space, we noticed sizeable M&A activity, with Hospira buying the Penicillin API business of Orchid for around R1,100 crore, Mitsui doing a secondary sale deal in Arch Pharma (incremental 26% stake) for around R372 crore and Mylan buying the Oncology API business of SMS Pharma for around R173 crore. In the injectible space, Claris entered into a uniquely structured joint venture agreement with two Japan-based drug makers Otsuka Pharmaceutical and Mitsui & Co in a deal valued at R1,313 crore.
- At least 65 EVMs replaced in six Lok Sabha seats in Assam
- Twitter cofounder talks of 26/11, Indian farmers in new book
- UP records over 24 pc voter turnout till 11 AM, 20 per cent turnout in Chhattisgarh
- Arvind Kejriwal lashes out at BJP for attack on Somnath Bharti
- ANF official accused of killing youth a gallantry award winner
- Maharashtra: Poor turnout till 9 am in third phase of polling